JP Morgan Chase
XBI icon

JP Morgan Chase’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

JP Morgan Chase’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$286M Sell
1,805,715
-4,425,660
-71% -$598M 0.02% 625
2026
Q1 		$740M Buy
6,231,375
+2,965,686
+91% +$370M 0.05% 322
2025
Q4 		$398M Sell
3,265,689
-10,273,049
-76% -$1.18B 0.03% 463
2025
Q3 		$1.36B Buy
13,538,738
+2,900,633
+27% +$261M 0.08% 228
2025
Q2 		$882M Buy
10,638,105
+268,399
+3% +$21.4M 0.06% 289
2025
Q1 		$841M Buy
10,369,706
+2,360,858
+29% +$211M 0.06% 275
2024
Q4 		$721M Sell
8,008,848
-4,266,737
-35% -$413M 0.05% 304
2024
Q3 		$1.21B Sell
12,275,585
-49,705
-0.4% -$4.88M 0.09% 209
2024
Q2 		$1.14B Buy
12,325,290
+4,479,443
+57% +$402M 0.09% 209
2024
Q1 		$744M Buy
7,845,847
+3,747,406
+91% +$348M 0.06% 285
2023
Q4 		$366M Sell
4,098,441
-780,484
-16% -$58M 0.04% 438
2023
Q3 		$356M Sell
4,878,925
-205,327
-4% -$16.4M 0.04% 396
2023
Q2 		$423M Sell
5,084,252
-2,450,219
-33% -$205M 0.05% 350
2023
Q1 		$574M Buy
7,534,471
+4,835,071
+179% +$401M 0.07% 282
2022
Q4 		$224M Buy
2,699,400
+162,805
+6% +$13.2M 0.03% 484
2022
Q3 		$201M Buy
2,536,595
+1,822,559
+255% +$154M 0.03% 491
2022
Q2 		$53M Buy
714,036
+256,652
+56% +$19.3M 0.01% 1003
2022
Q1 		$41.1M Buy
457,384
+239,398
+110% +$22.1M 0.01% 1271
2021
Q4 		$24.4M Sell
217,986
-2,422,464
-92% -$292M ﹤0.01% 1647
2021
Q3 		$332M Sell
2,640,450
-1,912,098
-42% -$246M 0.04% 424
2021
Q2 		$616M Sell
4,552,548
-2,240,031
-33% -$295M 0.07% 276
2021
Q1 		$921M Buy
6,792,579
+5,825,292
+602% +$872M 0.12% 182
2020
Q4 		$136M Sell
967,287
-9,572,202
-91% -$1.23B 0.02% 666
2020
Q3 		$1.18B Sell
10,539,489
-35,855
-0.3% -$4.02M 0.2% 111
2020
Q2 		$1.18B Buy
10,575,344
+721,657
+7% +$71.1M 0.23% 102
2020
Q1 		$763M Buy
9,853,687
+9,752,095
+9,599% +$864M 0.18% 124
2019
Q4 		$9.66M Sell
101,592
-6,519,760
-98% -$564M ﹤0.01% 2144
2019
Q3 		$505M Buy
6,621,352
+2,648,125
+67% +$220M 0.1% 216
2019
Q2 		$341M Sell
3,973,227
-788,686
-17% -$67.3M 0.07% 302
2019
Q1 		$431M Buy
4,761,913
+1,720,255
+57% +$146M 0.09% 249
2018
Q4 		$218M Sell
3,041,658
-224,057
-7% -$18.1M 0.05% 372
2018
Q3 		$313M Buy
3,265,715
+1,622,372
+99% +$157M 0.06% 328
2018
Q2 		$156M Buy
1,643,343
+180,743
+12% +$16.6M 0.03% 510
2018
Q1 		$128M Buy
1,462,600
+573,431
+64% +$52.4M 0.03% 541
2017
Q4 		$75.5M Sell
889,169
-1,139,375
-56% -$95.4M 0.02% 780
2017
Q3 		$174M Sell
2,028,544
-1,004,305
-33% -$80.5M 0.04% 451
2017
Q2 		$234M Sell
3,032,849
-346,845
-10% -$24.6M 0.05% 365
2017
Q1 		$234M Buy
3,379,694
+2,229,892
+194% +$150M 0.05% 360
2016
Q4 		$68.1M Buy
1,149,802
+436,816
+61% +$27M 0.02% 746
2016
Q3 		$47.3M Sell
712,986
-1,633,237
-70% -$101M 0.01% 867
2016
Q2 		$127M Sell
2,346,223
-762,989
-25% -$41.8M 0.03% 496
2016
Q1 		$161M Sell
3,109,212
-812,209
-21% -$42.2M 0.04% 430
2015
Q4 		$275M Buy
3,921,421
+2,498
+0.1% +$170K 0.07% 304
2015
Q3 		$244M Sell
3,918,923
-354,592
-8% -$27.9M 0.07% 308
2015
Q2 		$359M Buy
4,273,515
+535,992
+14% +$41.7M 0.08% 263
2015
Q1 		$281M Sell
3,737,523
-2,721,258
-42% -$190M 0.06% 335
2014
Q4 		$401M Sell
6,458,781
-292,095
-4% -$16.7M 0.09% 254
2014
Q3 		$351M Buy
6,750,876
+300,876
+5% +$15.3M 0.08% 270
2014
Q2 		$331M Sell
6,450,000
-306,282
-5% -$13.8M 0.08% 277
2014
Q1 		$321M Buy
6,756,282
+2,316
+0% +$119K 0.09% 252
2013
Q4 		$293M Sell
6,753,966
-600,375
-8% -$24.9M 0.08% 265
2013
Q3 		$317M Buy
7,354,341
+754,224
+11% +$30.6M 0.09% 246
2013
Q2 		$229M Buy
+6,600,117
New +$232M 0.07% 288

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $72.7B AUM 39.36% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $2.12B AUM 67.44% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM

JP Morgan Chase's XBI Position: Q2 2026 in Review

JP Morgan Chase reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 71% in Q2 2026, selling an estimated $598M and leaving 1,805,715 shares worth $286M. The position accounts for 0.02% of the portfolio, ranked #625.

JP Morgan Chase first reported a position in XBI in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.36B in Q3 2025. 739 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • JP Morgan Chase held 1,805,715 shares of State Street SPDR S&P Biotech ETF worth $286M as of Q2 2026.
  • JP Morgan Chase sold 4,425,660 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $598M.
  • State Street SPDR S&P Biotech ETF made up 0.02% of JP Morgan Chase's portfolio in Q2 2026, its #625 holding.
  • JP Morgan Chase first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 53 quarters since.
  • JP Morgan Chase's State Street SPDR S&P Biotech ETF position peaked at $1.36B in Q3 2025.
  • 739 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.